Literature DB >> 16988998

A comparison of the prevalence of urinary incontinence in girls with cystic fibrosis, asthma, and healthy controls.

S A Prasad1, I M Balfour-Lynn, S B Carr, S L Madge.   

Abstract

Urinary incontinence (UI) is recognized as a significant problem in adult females with cystic fibrosis and can often have a marked impact on day-to-day activities. The prevalence and severity of UI in the pediatric cystic fibrosis (CF) female population is less clear and there are no comparative data with healthy children or children with other respiratory disorders. An anonymous self-completed semi-structured questionnaire was used to study the prevalence rates of UI in girls with CF aged between 11 and 17 and compared it to age-matched asthmatic and healthy girls. The prevalence of UI in girls with CF was significantly higher (17/51, 33%) than the asthmatic (4/25, 16%) and healthy girls (2/27, 7%) (P = 0.02). It may manifest as early as 11 years of age and is associated with increasing lung disease. Surprisingly it is perceived as a relatively minor problem in terms of the distress it causes. Pediatric CF clinics should be routinely addressing UI as a potential problem in all girls from the age of 11 years.

Entities:  

Mesh:

Year:  2006        PMID: 16988998     DOI: 10.1002/ppul.20493

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  2 in total

1.  Prevalence of Pelvic Incontinence in Patients With Cystic Fibrosis.

Authors:  Fatima Neemuchwala; Fahmida Ahmed; Samya Z Nasr
Journal:  Glob Pediatr Health       Date:  2017-11-28

Review 2.  European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre.

Authors:  Steven Conway; Ian M Balfour-Lynn; Karleen De Rijcke; Pavel Drevinek; Juliet Foweraker; Trudy Havermans; Harry Heijerman; Louise Lannefors; Anders Lindblad; Milan Macek; Sue Madge; Maeve Moran; Lisa Morrison; Alison Morton; Jacquelien Noordhoek; Dorota Sands; Anneke Vertommen; Daniel Peckham
Journal:  J Cyst Fibros       Date:  2014-05       Impact factor: 5.482

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.